Skip to main content
OpenTrials
Completed

NCT Number: NCT01053845

Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain

Several studies showed that activity of down inhibitor bundle is weakened in different painful pathologies as the fibromyalgy or the trigeminal nevralgy.

The purpose of the protocol is to study the working of down inhibitor bundle at patients suffering of neuropathic pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Chu Clermont-Ferrand

Clermont-Ferrand, 63003, France

About this study

Prospective study with comparison groups

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • neuropathic patients group
  • Patient suffering of peripheral neuropathic pain
  • 18 years old women or men at least

Exclusion criteria

  • • Healthy volunteers
  • 18 years old women or men at least

Treatment and study plan

Neuropathic pain

Other

to study the working of down inhibitor bundle at patients suffering of neuropathic pain

Primary outcomes

  1. Comparison of the amplitude of N2P2 waves between healthy volunteers and patients suffering of peripheral neuropathic pain.

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Collaborators

  • Grünenthal GmbH

Registry information

Acronym: PhyDoNe

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jan 21, 2010
Registry last updated
Jul 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.